crsp climb higher first clinic
last week crsp announc result overal result surpass
expect patient number two tdt fairli sever
patient transfus annual bl sae occur relat
condit total hb level reach incl hbf surpass bar
hb patient ti month importantli f-cell underlin
advantag crispr scd patient four-month follow-up experienc
seven vocs/i bl hbf reach month four beat expect total hb
level patient free voc data preliminari
believ warrant read-across ex-vivo project base crsp abil
execut manufactur cell transplant pt
updat impli extra time enjoy disneyland late-
break abstract also deliv first-in-human data crsp technolog
encourag earli result demonstr us crsp abil execut
manufactur cell transplant trial execut believ read-across
cart project rais pt rais po adjust est
tdt patient transfus annual bl manag point
sever -thal allow read-across cohort
sae occur relat condit total hb level
reach includ hbf surpass bar hb
requir ti show seven week lentiglobin show
tdt patient ti month patient underw phlebotomi
iron chelat order normal iron content organ especi liver
part normal follow-up importantli f-cell peripher blood underlin
advantag use crispr achiev pancellular express bi-allel
edit frequenc present expect updat futur meet
scd patient four-month follow-up experienc seven vocs/i bl hbf
reach month four beat expect shrna work
boston children hospit show hbf level rang
show one patient week seven total hb level
patient free voc vs bl
data preliminari view valid target
enhanc drug manufactur sever addit patient
none dose yet follow safe engraft second patient
 mandat protocol trial could rapidli expand
discuss data prof porteu et
gene-edit compani focus
develop transform gene-
base medicin seriou diseas
proprietari
year price histori crsp
analyst certif import disclosur see disclosur
assum progress tdt scd
assum crsp make progress allo cart asset heme
solid tumor
addit progress outsid model indic cf
view crsp well posit deliv valu via
sever asset move proof-of-concept poc clinic trial
overal view crsp develop strategi well
thought clinic pipelin focus improv
establish approach via crispr complex
project vivo edit pursu second wave
continu enrol phase i/ii studi
data sever patient
first patient dose trial
failur advanc clinic asst
calcul price target month use discount cash flow analysi discount rate tv growth rate
current model sale hemoglobinopathi probabl success po allogen car-t
po estim valu platform technolog compani model sever earli
stage project low po
risk includ failur delay clinic asset develop
exhibit climb climb studi design target enrol
primari endpoint
exhibit stage climb trial
exhibit climb first tdt patient transfus free
sustain hbf result one patient surpass bar
hb requir ti show seven week
lentiglobin show g/dl month
exhibit climb first scd patient hbf four month
infus beat expect shrna work
boston children hospit show hbf level rang
show one patient week seven total hb
level patient free voc vs bl
exhibit hbf highli pancellular peripher rbc climb
climb importantli f-cell peripher blood underlin
advantag use crispr achiev pancellular express bi-
allel edit frequenc present expect updat
exhibit increas pt previous base
increas po scd -thal previous data
preliminari believ warrant read across ex-vivo
project base crsp abil execut manufactur cell
transplant increas po cart project
previous well platform po
crispr crsp discount except per-shar data thousand except per-shar data revenu growth chang work work capit valu growth valu oppenheim valu per sharetermin valu growth rateequ valu per shareprob success probabl crsp outperform
probabl success
probabl success
probabl success
probabl success
probabl success
collabor revenu mileston
royalti adjust po ex-u
probabl success
good
outgo royalti
research devleop
adjust research develop non-gaap
share-bas compens
total share-bas compenst
gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compenst
total share-bas compens exclud non-gaap
loss equiti method invest
total non-oper income/ expens
earn tax loss
